BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 21235444)

  • 1. Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.
    Kohan R; Cismondi IA; Oller-Ramirez AM; Guelbert N; Anzolini TV; Alonso G; Mole SE; de Kremer DR; de Halac NI
    Curr Pharm Biotechnol; 2011 Jun; 12(6):867-83. PubMed ID: 21235444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses.
    Kousi M; Lehesjoki AE; Mole SE
    Hum Mutat; 2012 Jan; 33(1):42-63. PubMed ID: 21990111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and genetic characterization of neuronal ceroid lipofuscinoses (NCLs) in 29 Iranian patients: identification of 11 novel mutations.
    Panjeshahi S; Karimzadeh P; Movafagh A; Ahmadabadi F; Rahimian E; Alijanpour S; Miryounesi M
    Hum Genet; 2023 Aug; 142(8):1001-1016. PubMed ID: 37074398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.
    Specchio N; Ferretti A; Trivisano M; Pietrafusa N; Pepi C; Calabrese C; Livadiotti S; Simonetti A; Rossi P; Curatolo P; Vigevano F
    Drugs; 2021 Jan; 81(1):101-123. PubMed ID: 33242182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in CLN7/MFSD8 are a common cause of variant late-infantile neuronal ceroid lipofuscinosis.
    Kousi M; Siintola E; Dvorakova L; Vlaskova H; Turnbull J; Topcu M; Yuksel D; Gokben S; Minassian BA; Elleder M; Mole SE; Lehesjoki AE
    Brain; 2009 Mar; 132(Pt 3):810-9. PubMed ID: 19201763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the social amoeba Dictyostelium to study the functions of proteins linked to neuronal ceroid lipofuscinosis.
    Huber RJ
    J Biomed Sci; 2016 Nov; 23(1):83. PubMed ID: 27881166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuronal ceroid lipofuscinoses: classification and diagnosis.
    Wisniewski KE; Kida E; Golabek AA; Kaczmarski W; Connell F; Zhong N
    Adv Genet; 2001; 45():1-34. PubMed ID: 11332767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.
    Rosenberg JB; Chen A; Kaminsky SM; Crystal RG; Sondhi D
    Expert Opin Orphan Drugs; 2019; 7(11):473-500. PubMed ID: 33365208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neuronal ceroid lipofuscinoses: mutations in different proteins result in similar disease.
    Weimer JM; Kriscenski-Perry E; Elshatory Y; Pearce DA
    Neuromolecular Med; 2002; 1(2):111-24. PubMed ID: 12025857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses.
    Sima N; Li R; Huang W; Xu M; Beers J; Zou J; Titus S; Ottinger EA; Marugan JJ; Xie X; Zheng W
    Orphanet J Rare Dis; 2018 Apr; 13(1):54. PubMed ID: 29631617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
    Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
    Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New mutations in the neuronal ceroid lipofuscinosis genes.
    Mole SE; Zhong NA; Sarpong A; Logan WP; Hofmann S; Yi W; Franken PF; van Diggelen OP; Breuning MH; Moroziewicz D; Ju W; Salonen T; Holmberg V; Järvelä I; Taschner PE
    Eur J Paediatr Neurol; 2001; 5 Suppl A():7-10. PubMed ID: 11589012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses.
    Mole SE; Williams RE; Goebel HH
    Neurogenetics; 2005 Sep; 6(3):107-26. PubMed ID: 15965709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy with recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis.
    Marques ARA; Di Spiezio A; Thießen N; Schmidt L; Grötzinger J; Lüllmann-Rauch R; Damme M; Storck SE; Pietrzik CU; Fogh J; Bär J; Mikhaylova M; Glatzel M; Bassal M; Bartsch U; Saftig P
    Autophagy; 2020 May; 16(5):811-825. PubMed ID: 31282275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of neuronal ceroid lipofuscinosis: mutation detection strategies.
    Getty AL; Rothberg PG; Pearce DA
    Expert Opin Med Diagn; 2007 Nov; 1(3):351-62. PubMed ID: 23489355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mouse models of neuronal ceroid lipofuscinoses: useful pre-clinical tools to delineate disease pathophysiology and validate therapeutics.
    Shacka JJ
    Brain Res Bull; 2012 May; 88(1):43-57. PubMed ID: 22502604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pheno/genotypic correlations of neuronal ceroid lipofuscinoses.
    Wisniewski KE; Zhong N; Philippart M
    Neurology; 2001 Aug; 57(4):576-81. PubMed ID: 11548735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell biology of the NCL proteins: What they do and don't do.
    Cárcel-Trullols J; Kovács AD; Pearce DA
    Biochim Biophys Acta; 2015 Oct; 1852(10 Pt B):2242-55. PubMed ID: 25962910
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.